Filgotinib, an oral JAK1 selective inhibitor with a rapid onset of action: results from the DARWIN 1 study in methotrexate inadequate response rheumatoid arthritis patients od Taylor, P, Westhovens, R, Vyncke, V, Meuleners, L, Van Der Aa, A, Harrison, P, Tasset, C

Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials od Tarrant, J, Galien, R, Li, W, Goyal, L, Pan, Y, Hawtin, R, Zhang, W, Van Der Aa, A, Taylor, P

Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid od Taylor, P, Tarrant, J, Zhao, L, Gindin, Y, Mirza, A, Harrison, P, Tasset, C, Galien, R, Van der Aa, A, Downie, B

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient r... od Westhovens, R, Taylor, P, Alten, R, Pavlova, D, Enriquez-Sosa, F, Mazur, M, Greenwald, M, Van der Aa, A, Vanhoutte, F, Tasset, C, Harrison, P

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase... od Mease, P, Coates, L, Helliwell, P, Stanislavchuk, M, Rychlewska-Hanczewska, A, Dudek, A, Abi-Saab, W, Tasset, C, Meuleners, L, Harrison, P, Besuyen, R, Van Der Aa, A, Mozaffarian, N, Greer, J, Kunder, R, Van Den Bosch, F, Gladman, D